Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®: A Retrospective Study (PROTRACT)

Trial Profile

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®: A Retrospective Study (PROTRACT)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Dimethyl fumarate (Primary) ; Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms PROTRACT
  • Most Recent Events

    • 14 Jun 2017 Planned End Date changed from 1 May 2017 to 1 Jul 2017.
    • 14 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 17 Sep 2016 Interim analysis results will be available in third quater 2016, with final results expected by end of 2016 as reported in trial design presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top